FGL-1 plasma levels correlate with markers of inflammation and severe disease during SARS-CoV-2 infection
Open Access
- 31 July 2026
- journal article
- research article
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 439
Abstract
Background: Fibrinogen-like protein 1 (FGL-1), primarily secreted by the liver, modulates immune responses and is upregulated in patients with hepatocellular carcinoma. FGL-1 affects T-cell function by interacting with lymphocyte-activation gene 3 (LAG-3), and blocking this interaction can enhance T-cell activity, making it a potential therapeutic target. In coronavirus disease 2019 (COVID-19), the upregulation of immune checkpoints on T cells, particularly LAG-3, is associated with disease severity. Liver inflammation and damage are well-known features of COVID-19 pathogenesis; however, little is known about FGL-1 expression patterns in COVID-19 and other infectious diseases. Methods: In a cohort of 65 patients with COVID-19 and 33 healthy donors, plasma FGL-1 levels were measured, and their correlations with clinical parameters and the course of the disease were evaluated. Additionally, both bulk and severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-specific T-cell immune phenotypes, as well as SARS-CoV-2-specific immune responses were comprehensively characterized and measured using multicolor flow cytometry and pMHC multimer technology. Results: Plasma FGL-1 levels were elevated in patients with COVID-19 and correlated with IL-6 and disease severity. LAG-3 was significantly upregulated on bulk and COVID-19-specific CD8 + T cells and was co-expressed with T-cell activation markers (CD38, HLA-DR) and inhibitory receptors (PD-1, TIGIT). Conclusion: These findings suggest a role for FGL-1 in the pathogenesis of COVID-19, potentially through modulation of T-cell activation and function via LAG-3, and may also be relevant in other hyperinflammatory conditions where immune modulation plays a role.Keywords
This publication has 54 references indexed in Scilit:
- Fibrinogen‐like 1: A hepatokine linking liver physiology to hematologyHemaSphere, 2024
- Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapyActa Pharmaceutica Sinica B, 2023
- FGL1-LAG3 axis impairs IL-10-Producing regulatory T cells associated with Systemic lupus erythematosus disease activityHeliyon, 2023
- The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinomaMolecular Biology Reports, 2022
- Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19iScience, 2021
- Liver Injury in Patients Hospitalized with Coronavirus Disease 2019 Correlates with Hyperinflammatory Response and Elevated Interleukin-6Hepatology Communications, 2020
- COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysisJournal of Medical Virology, 2020
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3Cell, 2019
- Costimulatory and Coinhibitory Receptor Pathways in Infectious DiseaseImmunity, 2016
- Fibrinogen-like protein 1, a hepatocyte derived protein is an acute phase reactantBiochemical and Biophysical Research Communications, 2008